Fractyl Health (GUTS) Gains from Sales and Divestitures (2024 - 2025)
Fractyl Health (GUTS) reported Gains from Sales and Divestitures of $22500.0 for Q4 2025, down 96.28% year-on-year from $604509.0 in Q4 2024, and down 96.28% quarter-over-quarter from $604509.0 in Q4 2024.
Fractyl Health (GUTS) has 2 years of Gains from Sales and Divestitures data on file, last reported at $22500.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 96.28% year-over-year to $22500.0; the trailing twelve-month figure through Dec 2025 stood at $22500.0 (down 96.28% YoY), and the FY2025 full-year result was $22500.0, down 96.28% from the prior year.
- Gains from Sales and Divestitures for Q4 2025 stood at $22500.0, down from $604509.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $604509.0 in Q4 2024 and bottomed at $22500.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22,500.00 |
| Dec 31, 2025 | 22,500.00 |
| Dec 31, 2024 | 604,509.00 |
| Dec 31, 2024 | 604,509.00 |